Inhaled mRNA Tumor-associated Antigen Dry Powder Vaccine in Advanced Lung Cancer and Lung Metastasis of Solid Tumors.

Inclusion Criteria:

• Able to understand and comply with the requirements of the study protocol,voluntarily participate in the trial, and sign a written informed consent form (ICF).

• Must be at least 18 (inclusive) at the time of signing the ICF, and both male andfemale participants are eligible.

• Histologically or cytologically confirmed as advanced lung cancer (driver genenegative) or advanced solid tumors with lung metastasis, and having failed priorstandard treatments or having no standard treatment options.

• Agree to provide fresh tumor tissue samples or archived tumor tissue samples withinthe past three years.

• Presence of at least one measurable lesion as defined by RECIST V1.1

• Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-1

• Organ function must be adequate at screening (no need for blood transfusion,hematopoietic growth factors, human albumin, or medications for correction within 14days prior to first treatment), specifically defined as: a) Hematology: Absoluteneutrophil count ≥1.5×10^9/L; platelet count ≥90×10^9/L; hemoglobin ≥90 g/L (9g/dL). b) Liver Function: Serum total bilirubin (TBIL) ≤1.5× upper limit of normal (ULN); for patients with liver metastasis or a history/suspected history ofGilbert's syndrome (persistent or recurrent hyperbilirubinemia, primarilyunconjugated bilirubin, with no evidence of hemolysis or liver pathology), TBIL ≤3×ULN; for patients without liver metastasis, alanine aminotransferase (ALT) andaspartate aminotransferase (AST); for patients with liver metastasis, ALT or AST ≤5×ULN. c) Renal Function: Creatinine (Cr) ≤1.5×ULN or creatinine clearance (CLcr) ≥60 mL/min (calculated using the Cockcroft-Gault formula, see Attachment 3); urinedipstick test result showing urinary protein <2+; for patients with baseline urinedipstick showing protein ≥2+, a 24-hour urine collection should be conducted, andthe protein content in the 24-hour urine should be <1 g. d) Cardiac Function:Echocardiography showing left ventricular ejection fraction (LVEF) >50%. e)Pulmonary Function: Shortness of breath ≤Grade 1 as per the National CancerInstitute Common Terminology Criteria for Adverse Events (NCI CTCAE), and outdoorambient air oxygen saturation (SpO₂) ≥92%.

• Expected life expectancy ≥12 weeks.

• Female patients of childbearing potential and male patients (and their femalepartners) must use highly effective contraception from the screening period until atleast 6 months after the last dose of the study drug. Patients must not plan toconceive, donate sperm, or donate eggs during this period

Exclusion Criteria:

• Patients with lung cancer who have concurrent other types of malignant tumors or arediagnosed with multiple primary malignancies, except for the following: completelyresected basal cell carcinoma and squamous cell carcinoma of the skin, completelyresected any type of carcinoma in situ.

• Symptomatic central nervous system metastasis; for patients with asymptomatic brainmetastasis or those whose symptoms have been stable for ≥2 weeks after treatment ofbrain metastasis, they may participate in this study if they meet all the followingcriteria: measurable lesions in the lungs; cessation of steroid treatment 14 daysprior to the first trial product dose.

• Patients with chronic obstructive pulmonary disease (COPD), asthma, or allergies topollen or dust.

• Patients suspected of having active or latent tuberculosis infection, based oninterferon-γ release assay results, clinical symptoms, and/or chest imaging findings (patients with evidence of adequately treated prior active tuberculosis infectionmay be enrolled after assessment by the investigator; for latent tuberculosis,patients must have completed at least 4 weeks of anti-tuberculosis treatment, withno liver function impairment [ALT ≤3×ULN, AST ≤3×ULN], and after the investigatorassesses that the risk is manageable, they may be considered for continued screeningor enrollment).

• History of interstitial lung disease (e.g., idiopathic pulmonary fibrosis ororganizing pneumonia), or active, non-infectious pneumonia requiringimmunosuppressive treatment such as corticosteroids.

• Patients with active autoimmune diseases requiring therapeutic intervention.

• History of serious bleeding disorders; or those with coagulation dysfunction (asindicated by laboratory tests or medical history) who are deemed by the investigatorto be unsuitable for the trial treatment.

• History or current diagnosis of cardiovascular disease, including any of thefollowing: a) Recent myocardial infarction or coronary artery bypass grafting (CABG)within the past 6 months; b) Uncontrolled congestive heart failure; c) Unstableangina (within the past 6 months); d) Clinically significant (symptomatic)arrhythmias (e.g., sustained ventricular tachycardia, clinically significant second-or third-degree atrioventricular block without a pacemaker).

• Clinically uncontrolled third-space fluid accumulation (e.g., pleuraleffusion/pericardial effusion; patients with effusions that do not require drainageor those whose effusions have not increased significantly after stopping drainagefor 3 days may be included).

• Severe infection requiring intravenous antibiotic treatment or hospitalization atscreening, or any uncontrolled active infection within 4 weeks prior to the firstdose of the trial product.

• History of severe allergic reactions, or known allergy to any active or inactivecomponent of BMD006 or PD-1 inhibitors.

• Any other metabolic, hematological, renal, hepatic, pulmonary, neurological,endocrine, cardiac, or gastrointestinal disease that, in the investigator's opinion,may present unacceptable risks to the patient during treatment.

• Presence of unresolved toxicity from prior anti-tumor treatments before the firstdose of the study product, which has not recovered to Grade 0 or 1 (excludingalopecia) (severity assessed according to NCI CTCAE v5.0).

• Positive test results for hepatitis B at screening [defined as: ① Hepatitis Bsurface antigen (HBsAg) positive; ② HBsAg negative but hepatitis B core antibody (HbcAb) positive (further testing through hepatitis B virus deoxyribonucleic acid [HBV DNA] is required, and patients with HBV DNA levels exceeding the normal limitfor the test method must be excluded)], positive hepatitis C antibody (HCV Ab) [further testing through hepatitis C virus ribonucleic acid (HCV RNA) is required,and patients with HCV RNA levels exceeding the normal limit for the test method mustbe excluded], or positive human immunodeficiency virus antibody (HIV Ab).

• Underwent major surgery within 4 weeks prior to the first dose of the trial product (cranial, thoracic, or abdominal surgery) or has an unresolved wound, ulcer, orfracture. Note: Thoracoscopic surgery and mediastinoscopy will not be consideredmajor surgery. Patients who are ≥2 weeks post-surgery or who are deemed eligible bythe investigator may be included in the study.

• Previously received similar products or treatments.

• Received other anti-tumor treatments (radiotherapy, chemotherapy, endocrine therapy,targeted therapy, immunotherapy, etc.) within 4 weeks or 5 half-lives (whichever islonger) prior to the first dose of the trial product.

• Received systemic immunosuppressive agents (e.g., systemic corticosteroids) within 3months prior to the first dose of the trial product.

• Received or planned to receive live or attenuated live vaccines within 3 monthsprior to the first dose of the trial product or during the study.

• Pregnant or breastfeeding women.

• Participated in any clinical drug trial (defined as being randomized and receivingtrial product treatment) within 3 months or 5 half-lives (whichever is longer) priorto screening.

• Any other condition deemed by the investigator to make the patient unsuitable forparticipation in the trial.